Barry K. Knight
Plus aucun poste en cours
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Marcus Irsfeld | M | - |
Trigen Holdings AG
 Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Göran Albert Ando | M | 75 |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Sanjay K. Kakkar | M | - |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | 12 ans |
| Oliver Boucher | M | - |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | 7 ans |
| Tony Kennedy | M | - |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | 7 ans |
| Charles Klotz | M | - |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Gunnar Magnus Modee Persson | M | 64 |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Bror Thomas Pollare | M | 71 |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Thomas F. Widmann | M | 77 |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Neil Graham | M | - |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Erich Schlick | M | 72 |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Allemagne | 11 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Barry K. Knight
- Réseau Personnel
